Skip to main content

Acceleration of Digitization of Clinical Development post COVID-19

Thank you

This live web event has ended. Thank you for attending.

Contributors

  • Maria Perkinson, VP Strategic Business Process, NUROCOR

    Maria brings more than 20 years experience delivering business and IT transformation solutions. She has extensive experience in clinical trial operations and management and is an expert in applying program management, process improvement, innovation,and change management methodologies. Maria has led many large-scale, global initiatives within the pharmaceutical industry that include process optimization and technology improvements, driving operational efficiencies.
    Her technical experience, background in analytics and process improvement coupled with her ability to bridge disparate organizations and disciplines brings critical value as innovation and data technology play increasingly important role.

  • Barrie Nelson, Chief Standards Officer, NUROCOR

    Barrie Nelson is passionate about bringing order to clinical data and clinical development processes. Barrie’s BioPharma experience spans Biostatistics, Clinical Data Management, and Data Standards organizations. Barrie spent a brief time as the lead of foundational standards development at CDISC, after many years as a volunteer and team lead. Now, as a founder of Nurocor, his experience and perspective are put to use in the development of the innovative and paradigm shifting Nurocor Clinical Platform solution, a solution that enables Nurocor customers to realize a fully digital clinical development process.

  • Sagar Anisingaraju, Chief Strategy Officer, Saama Technologies

    Named to this year’s prestigious PharmaVOICE 100 list of the most inspiring individuals in life sciences, Sagar Anisingaraju guides the concepts, design, and development of innovative data and analytics solutions at Saama that generate successful business outcomes. Sagar leads Saama’s transformation journey, creating focus areas, business models, and repeatable offerings. His passion is to help pharma and biotech create intelligent analytical solutions to operationalize insights and solve drug development/delivery business challenges.
    Sagar holds multiple patents related to AI applications. He has authored and published several technical articles and blogs on how AI-powered solutions can bring about a Pharma version of Moore’s Law that reduces the cost and duration of clinical trials by an order of magnitude. His new novel, Kuchela.AI, tells the story of a technologist’s journey of self-awareness that radically advances the world through AI with a higher purpose.

  • Malaikannan Sankarasubbu, Vice President AI Research, Saama Technologies

    Malaikannan Sankarasubbu leads Saama’s AI Research group. He was previously Founder and CTO of Natural Language Understanding Startup. Malai has authored multiple peer-reviewed scientific papers that has been published in major conferences like ISCB, ICAART, ACL etc. Malai strongly believes that AI would play a major role in Optimizing and Acceleratin clinical trials.

  • Ralph Russo, Ralph Russo, Senior Director, Pfizer

    Ralph J. Russo, CCDM, is the Global Head Clinical Database Management and Standards at Pfizer. In this role, Ralph is responsible for all Clinical Trial database builds across various systems used at Pfizer.. Ralph has over 32 years’ experience in the pharmaceutical industry.

    Prior to joining Pfizer, Ralph worked at Merck where he was responsible for various groups including External Data Acquisition and Clinical Database Management. Ralph also has 14 years’ experience at Wyeth where he was responsible for designing clinical trial databases using the Oracle Clinical suite of applications. Prior to this, Ralph worked on various drug development teams in support of Discovery Research as a Research Chemist at Wyeth.

    Ralph has an MBA with a concentration in Management Information Systems from Temple University’s Fox School of Business, a Master of Science degree in Chemistry from Seton Hall University, and a Bachelor of Arts degree in Chemistry from Rutgers University.

  • Demetris Zambas, Head of Data Monitoring and Management, Pfizer

    Demetris is currently VP and Global Head of Data Monitoring and Management at Pfizer. Demetris started his career as a Laboratory Scientist in 1991 and transitioned into the Clinical Development space where he held roles of increasing responsibilities in Trial Management and Monitoring and led the implementation of the company’s first Clinical Trial Management system. In 2000, Demetris was a member and eventually the leader of the team which executed the industry’s first Tech- Transfer of a web based EDC system. He eventually led the Data Management and Standards organization and continued on to Merck & Co. following the merger in 2009. Subsequently Demetris was Vice President of Data Management at Novartis AG from 2014 to 2017. Since 2017 Demetris leads Pfizer’s Data Management and Risk Based Monitoring line functions in a new transformation; developing and transitioning into an internal operating model across multiple geographic sites in support of Pfizer’s portfolio. He also leads the Data and Automation work stream as part of Pfizer’s Development-wide transformation effort. He currently serves on multiple Boards, including SCDM’s Advisory Board, has served on the Board of Trustees and was the 2016 Chair.

  • Joanna Florek-Marwitz, Head Risk Managemet and Data Quality, UCB

October 6, 2020
Tue 5:00 PM CEST

Duration 1H 30M

This live web event has ended.